Clinical Trials
6
1 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
2011
Active, not recruiting
1
16.7%
Completed
3
50.0%
Recruiting
2
33.3%
No approval data available
- Panbela Therapeutics secured a $12 million financing commitment from Nant Capital to advance its clinical programs. - A Phase I dose escalation study of CPP-1X-S (eflornithine sachets) has begun in STK11 mutant non-small cell lung cancer (NSCLC). - The Phase III ASPIRE trial for ivospemin in pancreatic cancer is progressing, with interim analysis expected in Q1 2025.
- Panbela Therapeutics has dosed the first patient in a Phase I trial evaluating CPP-1X-S (eflornithine sachets) in STK11 mutant non-small cell lung cancer (NSCLC). - The Phase I dose escalation study aims to determine the maximum tolerated dose of eflornithine in combination with Keytruda, an immune checkpoint inhibitor. - Initial Phase I data is expected by mid-2025, with a Phase II efficacy trial planned to commence in 2024 to assess the combination's clinical potential. - The trial will explore polyamine modulation via CPP-1X-S to potentially restimulate the immune system in these historically hard-to-treat tumors.
